CSIMarket
 
Biophytis Sa  (BPTS)
Other Ticker:  
 
 
Price: $0.4069 $-0.07 -14.946%
Day's High: $0.419 Week Perf: -16.7 %
Day's Low: $ 0.37 30 Day Perf: -27.1 %
Volume (M): 169 52 Wk High: $ 4.89
Volume (M$): $ 69 52 Wk Avg: $1.53
Open: $0.42 52 Wk Low: $0.35



 Market Capitalization (Millions $) 48
 Shares Outstanding (Millions) 118
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) 0

Biophytis Sa
Biophytis SA is a clinical-stage biotechnology company based in France. The company focuses on developing innovative therapeutics to treat age-related diseases, with a particular focus on neuromuscular and metabolic diseases. Biophytis is known for its expertise in the field of mitochondria, which are often implicated in age-related conditions.

The company's lead product candidate is Sarconeos (BIO101), which is being developed for the treatment of sarcopenia, a progressive decline in muscle mass, strength, and function that occurs with aging. Sarconeos is currently in Phase 2b/3 clinical trials and has shown promising results in improving muscle function in patients with sarcopenia.

Biophytis has also developed other drug candidates targeting various age-related diseases, including Macuneos (BIO201) for the treatment of dry age-related macular degeneration and COVA (BIO34) for the treatment of COVID-19 patients with respiratory failure. These drug candidates are in preclinical or early clinical stages of development.

Overall, Biophytis SA is dedicated to advancing the field of biotechnology and developing innovative therapies to address the unmet needs of aging populations.


   Company Address: Sorbonne Universityâ??BC 9 Paris 75005
   Company Phone Number: 1 44 27 23 00   Stock Exchange / Ticker: NASDAQ BPTS
   BPTS is expected to report next financial results on April 17, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Neurogene Inc

Neurogene Inc. Breaks Ground in Rare Neurological Disorder Research with Expansion of NGN-401 Trial

Neurogene Inc., a leading clinical-stage company specializing in genetic medicines for rare neurological disorders, has recently announced its plans to expand its Phase 1/2 gene therapy clinical trial for NGN-401. This trial is particularly focused on female pediatric patients suffering from Rett syndrome, a debilitating genetic disorder that primarily affects the nervous system. In addition to expanding the trial, Neurogene Inc. also aims to improve the enrollment process to allow for faster participation and assessment.
Rett syndrome, although considered a rare condition, has a profound impact on the lives of patients and their families. It predominantly affects females and is caused by mutations in the MECP2 gene. Symptoms typically appear between six to eighteen months after birth and result in severe impairments in physical, cognitive, and social functioning. Children with Rett syndrome often lose purposeful hand skills, experience regression in language and motor abilities, exhibit repetitive hand movements, and develop respiratory irregularities. Currently, there is no cure for Rett syndrome, and treatment primarily focuses on managing symptoms and providing supportive care.

Eyenovia Inc

Eyenovia Inc Faces Challenges as Shares Plummet and Future Prospects Remain Uncertain



Eyenovia Inc, a major pharmaceutical preparations company, has witnessed a significant drop in its shares over the past month. This decline adds to the year-to-date poor performance. Additionally, the company is currently trading on the NASDAQ well below its 52-week average. These developments raise concerns about Eyenovia's future prospects and its ability to overcome these challenges. Furthermore, factors such as a co-promotion agreement and recent financial results also contribute to the uncertainty surrounding the company's future.
1. Co-Promotion Agreement with NovaBay Pharmaceuticals:
Eyenovia's strategic partnership with NovaBay Pharmaceuticals aims to expand market presence and provide a wider range of ophthalmic solutions. Under this agreement, NovaBay will market Eyenovia's Clobetasol propionate ophthalmic suspension, while Eyenovia will promote NovaBay's Avenova Antimicrobial Lid and Lash Solution. This collaboration intends to effectively target eye care professionals across the United States. However, the impact and success of this agreement remain to be seen.

Avenue Therapeutics Inc

Among many companies, the ATXI reported as well its fourth quarter of 2023 performance

Avenue Therapeutics Inc, a prominent pharmaceutical company, has been making waves in the medical industry with its groundbreaking advancements in the treatment of various neurological disorders. Recently, the company presented its preclinical data on BAER-101 at the American Society for Experimental Neurotherapeutics Annual Meeting, showcasing its full suppression of seizure activity in absence epilepsy. This discovery has the potential to revolutionize anti-seizure drug development and significantly improve the lives of those affected by this condition.
Absence epilepsy is a neurological disorder characterized by intermittent episodes of unconsciousness and staring spells. It predominantly affects children and adolescents, often leading to academic and social challenges. The underlying cause of this condition involves abnormal electrical activity in the brain, resulting in seizures characterized by momentary lapses in consciousness. Prompt and effective treatment is crucial in preventing long-term complications and enhancing the quality of life for individuals with absence epilepsy.

Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com